Indian pharmaceutical companies are set for a strong recovery. Clarity on US tariff policies is expected to boost earnings. Lupin is highlighted as a top investment choice due to its strong product pipeline and consistent US market performance. RBL Bank is also identified as a promising turnaround story. These sectors are expected to perform well in the coming quarters.